Bonefos and the Consumption of Analgesics (BICAM)
Bonefos and the Consumption of Analgesics. Influence of Clodronate on Analgesics Consumption Among Patients With Bone Metastasis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Many locations, Czech Republic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Breast cancer or prostate cancer or multiple myeloma.
- Bone metastasis.
- Ability to use analgesics and clodronate 1600 mg/day.
Exclusion Criteria:
- Hypersensitivity to bisphosphonates.
- Clodronate in previous therapy.
- Concomitant use of other bisphosphonates.
- Serious renal insufficiency.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group1
|
Patients in regular clinical practice receiving Bonefos according to local drug information
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Analgesics consumption after 12 months of treatment with Bonefos in patients with bone metastases and breast or prostate cancer or multiple myeloma
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Decrease in pain measured by VAS (Visual Analogue Scale)
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 14236
- Bonefos
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Neoplasms
-
NCT04798326Completed
-
NCT03427632Unknown
-
NCT07379008CompletedBone Diseases | Bone Cysts | Bone Neoplasm | Enchondromatosis | Bone Defects
-
NCT07337018Not yet recruiting
-
NCT07113301Active, not recruitingMalignant Bone Tumor
-
NCT04178044Unknown
-
NCT07560410Not yet recruiting
-
NCT07193550Recruiting
Clinical Trials on Bonefos (Clodronate, BAY94-8393)
-
NCT01198457CompletedBreast Neoplasms | Prostatic Neoplasms | Multiple Myeloma | Osteolysis
-
NCT00009945Completed